Mitsubishi UFJ Asset Management Co. Ltd. Acquires 24,200 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 104.7% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 47,309 shares of the company's stock after purchasing an additional 24,200 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. owned approximately 0.14% of TransMedics Group worth $3,183,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the stock. CWM LLC boosted its holdings in TransMedics Group by 20.1% in the 1st quarter. CWM LLC now owns 925 shares of the company's stock valued at $62,000 after purchasing an additional 155 shares during the period. Campbell Newman Asset Management Inc. boosted its holdings in TransMedics Group by 1.4% in the 1st quarter. Campbell Newman Asset Management Inc. now owns 11,619 shares of the company's stock valued at $782,000 after purchasing an additional 166 shares during the period. Hager Investment Management Services LLC boosted its holdings in TransMedics Group by 38.3% in the 1st quarter. Hager Investment Management Services LLC now owns 740 shares of the company's stock valued at $50,000 after purchasing an additional 205 shares during the period. Nisa Investment Advisors LLC boosted its holdings in TransMedics Group by 1.6% in the 1st quarter. Nisa Investment Advisors LLC now owns 15,824 shares of the company's stock valued at $1,065,000 after purchasing an additional 256 shares during the period. Finally, PNC Financial Services Group Inc. boosted its holdings in TransMedics Group by 13.8% in the 1st quarter. PNC Financial Services Group Inc. now owns 2,294 shares of the company's stock valued at $154,000 after purchasing an additional 278 shares during the period. 99.67% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have weighed in on TMDX shares. Canaccord Genuity Group increased their price target on shares of TransMedics Group from $129.00 to $142.00 and gave the company a "buy" rating in a report on Tuesday, July 15th. Needham & Company LLC restated a "hold" rating on shares of TransMedics Group in a research note on Tuesday, June 17th. Wall Street Zen upgraded shares of TransMedics Group from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Piper Sandler restated an "overweight" rating and issued a $145.00 price objective (up previously from $125.00) on shares of TransMedics Group in a research note on Wednesday, June 4th. Finally, Oppenheimer increased their price objective on shares of TransMedics Group from $130.00 to $150.00 and gave the company an "outperform" rating in a research note on Tuesday, June 17th. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $123.00.

TransMedics Group Price Performance

Shares of TMDX stock traded down $2.30 during mid-day trading on Thursday, reaching $129.74. The company's stock had a trading volume of 875,947 shares, compared to its average volume of 1,392,768. The company has a market cap of $4.42 billion, a P/E ratio of 68.42 and a beta of 2.09. The company has a debt-to-equity ratio of 1.61, a quick ratio of 9.17 and a current ratio of 9.86. The firm's 50-day moving average is $123.89 and its two-hundred day moving average is $99.05. TransMedics Group, Inc. has a 1-year low of $55.00 and a 1-year high of $177.37.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.48 by $0.44. The business had revenue of $157.37 million during the quarter, compared to analysts' expectations of $146.64 million. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The firm's revenue for the quarter was up 37.7% on a year-over-year basis. During the same quarter last year, the company posted $0.35 EPS. On average, research analysts predict that TransMedics Group, Inc. will post 1 earnings per share for the current year.

Insider Buying and Selling

In other news, Director David Weill sold 732 shares of TransMedics Group stock in a transaction that occurred on Friday, May 23rd. The shares were sold at an average price of $123.88, for a total transaction of $90,680.16. Following the completion of the sale, the director owned 12,134 shares in the company, valued at $1,503,159.92. The trade was a 5.69% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Edward M. Basile sold 5,000 shares of TransMedics Group stock in a transaction that occurred on Tuesday, May 27th. The stock was sold at an average price of $126.45, for a total transaction of $632,250.00. Following the sale, the director owned 2,866 shares of the company's stock, valued at approximately $362,405.70. This represents a 63.56% decrease in their position. The disclosure for this sale can be found here. Insiders sold 6,418 shares of company stock worth $818,833 in the last quarter. 7.00% of the stock is owned by corporate insiders.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.